Residual Cancer After Neoadjuvant Tx Predicts High-Risk Prostate Cancer Outcomes
Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.
Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.
Already Registered? Login here. REGISTER NOW Already registered?
Investigators analyzed the safety and efficacy of the HIF-PHI vadadustat vs ESA darbepoetin for the treatment of renal anemia within the United States.
Thrombotic microangiopathy on top of systemic lupus erythematosus (SLE) is associated with worse prognosis.
Jared S. Winoker, MD, addresses the wide range of stone burdens treated by the CVAC system for the study.
Registration for the 9th Baltic Meeting (Baltic24) is open. Register now and benefit from early fee.
Four days of education, innovation, networking and much more – AUA 2025 has brought the very best of urology together for one incredible annual meeting.…
The aim of these guidelines is to present the current evidence for the diagnosis and treatment of patients with cancer of the testis.
Pregnant women with systemic lupus erythematosus (SLE) who experience cardiovascular events are at high risk for adverse outcomes.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
We are seeking a proactive and detail-oriented fulltime Managing Editor at European Urology to oversee and manage topical collections within our urology journal portfolio.